CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
We are very excited to launch our new website! Please take a few moments to click around and explore...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...